Aptose Biosciences, Inc.
APTO Real Time Price USDRecent trades of APTO by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by APTO's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Fused pyrimidine compounds as brd4 and jak2 dual inhibitors and methods for use thereof Mar. 22, 2022
-
Patent Title: Aryl imidazoles for treatment of cancer Oct. 19, 2021
-
Patent Title: Compositions and methods for treating cancers Aug. 31, 2021
-
Patent Title: Aryl imidazoles and their use as anti-cancer agents Sep. 25, 2018
-
Patent Title: Compositions and methods for treating cancers Feb. 14, 2017
-
Patent Title: 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents Mar. 24, 2015
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of APTO in WallStreetBets Daily Discussion
Recent insights relating to APTO
Recent picks made for APTO stock on CNBC
ETFs with the largest estimated holdings in APTO
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view APTO Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.